Pneumococcal 20-Valent (PCV20)

PCV20 (Prevnar 20) is the latest generation pneumococcal conjugate vaccine covering 20 strains. Approved for adults 18+ and offers broader protection than older PCV13.

The Pneumococcal 20-Valent (PCV20) is recommended for 18 years and above. It falls under the Adult vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Pneumococcal 20-Valent (PCV20) has an efficacy of Comparable to PCV13 for shared serotypes; additional protection for 7 new serotypes. This means it provides significant protection against Pneumonia and Meningitis. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Injection site reactions; fatigue; headache; myalgia. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Pneumococcal 20-Valent (PCV20) should be avoided by: Severe allergic reaction to prior pneumococcal vaccine or diphtheria toxoid.. Always inform your healthcare provider of your full medical history before vaccination.

The Pneumococcal 20-Valent (PCV20) typically costs ₹4,500–₹6,000 private in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.